Education
About Us
Working with TipRanks
Follow Us
Inozyme Pharma (INZY)
NASDAQ:INZY
| Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -1.29M | $ -1.18M | $ -1.05M | $ -217.00K | $ -83.00K |
| Operating Income | $ -75.64M | $ -68.67M | $ -56.65M | $ -57.04M | $ -20.81M |
| EBITDA | $ -74.81M | $ -65.88M | $ -55.97M | $ -56.82M | $ -20.72M |
| Net Income | $ -71.17M | $ -65.45M | $ -56.41M | $ -55.84M | $ -18.62M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 188.59M | $ 127.87M | $ 111.80M | $ 159.90M | $ 47.13M |
| Total Assets | $ 200.85M | $ 139.19M | $ 123.54M | $ 169.36M | $ 47.94M |
| Total Debt | $ 46.59M | $ 6.78M | $ 3.37M | $ 1.29M | $ 0.00 |
| Net Debt | $ 12.00M | $ -26.14M | $ -19.95M | $ -158.61M | $ -31.61M |
| Total Liabilities | $ 60.37M | $ 20.80M | $ 14.27M | $ 11.26M | $ 81.16M |
| Stockholders' Equity | $ 140.48M | $ 118.59M | $ 109.27M | $ 158.10M | $ -33.22M |
| Cash Flow | |||||
| Free Cash Flow | $ -70.97M | $ -58.17M | $ -48.55M | $ -36.54M | $ -18.95M |
| Operating Cash Flow | $ -70.67M | $ -57.76M | $ -48.15M | $ -35.97M | $ -18.81M |
| Investing Cash Flow | $ -53.65M | $ -5.40M | $ 42.80M | $ -117.18M | $ -8.39M |
| Financing Cash Flow | $ 125.97M | $ 72.79M | $ 609.00K | $ 149.81M | $ 22.97M |